|

combination of Surufatinib and Envolizumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1

Indications

  • Head and Neck Cancer Squamous Cell Carcinoma1
  • Head and Neck Cancer1
  • Cancer1

Other1 trial

Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.